Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

AbbVie dips despite Street-beating Q2, raised guidance

By Sean Whooley | July 30, 2021

AbbvieAbbVie (NYSE:ABBV) shares took a hit today despite second-quarter results that topped the consensus forecast.

The North Chicago-based company posted profits of $769 million, or 42¢ per share, on sales of $14 billion for the three months ended June 30, 2021, marking a massive bottom-line gain from losses of -$739 million last year on sales growth of 33.9%.

Adjusted to exclude one-time items, earnings per share were $3.11, 2¢ ahead of Wall Street, where analysts were looking for sales of $13.6 billion.

“AbbVie delivered another strong quarter and our business continues to perform extremely well across the portfolio, with AbbVie’s new immunology assets contributing more than $1 billion of combined sales in the quarter,” AbbVie chairman & CEO Richard A. Gonzalez said in a news release. “The Allergan integration also continues to track exceptionally well, with both the neuroscience and aesthetics portfolios delivering double-digit sequential growth. Based upon the momentum of our business, we are raising our full-year 2021 EPS guidance and believe AbbVie is very well positioned for the long term.”

AbbVie said it now expects to log full-year adjusted EPS of between $12.52 and $12.62, an increase from previous projections of $12.37 to $12.57.

ABBV shares were down -1.5% $117.09 in midday trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up 1.4%.

Tell Us What You Think! Cancel reply

Related Articles Read More >

GSK
GSK finalizes Affinivax acquisition 
vaccine
U.S. government makes an additional 442,000 monkeypox vaccine doses available 
Biogen logo
Biogen is scaling back space outside Boston
Fresenius Kabi
Fresenius Kabi plans to add 2D barcodes to its pharmaceutical portfolio

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards